Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14784 | 1.00 | FASN (0.51) | FASNBRD4 | |
| SCHEMBL11909521 | 1.00 | FASN (0.51) | FASNBRD4 | |
| SCHEMBL11909581 | 0.94 | FASN (0.59) | FASNBRD4 | |
| SCHEMBL22220816 | 0.94 | FASN (0.59) | FASNBRD4 | |
| SCHEMBL14786 | 0.94 | FASN (0.59) | FASNBRD4 | |
| SCHEMBL22220820 | 0.90 | FASN (0.54) | FASNBRD4 | |
| SCHEMBL11909653 | 0.90 | FASN (0.54) | FASNBRD4 | |
| SCHEMBL14783 | 0.90 | FASN (0.54) | FASNBRD4 | |
| SCHEMBL22220926 | 0.89 | FASN (0.55) | FASNBRD4 | |
| SCHEMBL11909504 | 0.89 | FASN (0.55) | FASNBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020150423-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | FASN 2790/4885BRD4 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.